Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2

Carcinogenesis

Volumn 29, Issue 6, 2008, Pages 1235-1243

  Wang, Xiao Jun ^a   Sun, Zheng ^a   Villeneuve, Nicole F ^a   Zhang, Shirley ^a   Zhao, Fei ^a   Li, Yanjie ^a   Chen, Weimin ^a   Yi, Xiaofang ^b   Zheng, Wenxin ^b   Wondrak, Georg T ^a   Wong, Pak Kin ^c   Zhang, Donna D ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEASOME; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SMALL INTERFERING RNA; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2;

ADJUVANT THERAPY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER CLASSIFICATION; CELL PROTECTION; CONTROLLED STUDY; DOWN REGULATION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME DEGRADATION; EVIDENCE BASED MEDICINE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; NEUROBLASTOMA; PRIORITY JOURNAL; UBIQUITINATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; NF-E2-RELATED FACTOR 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 46949099638     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn095     Document Type: Article

References (57)

1. Zhang,D.D. (2006) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev., 38, 769-789.
2. Venugopal,R. et al. (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:qUinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. USA, 93, 14960-14965.
3. Itoh,K. et al. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev., 13, 76-86.
4. Kobayashi,A. et al. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol., 24, 7130-7139.
5. Zhang,D.D. et al. (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol., 24, 10941-10953.
6. Kobayashi,M. et al. (2006) Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul., 46, 113-140.
7. Sun,Z. et al. (2007) Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol. Cell. Biol., 27, 6334-6349.
8. Lee,J.M. et al. (2003) Identification of the NF-E2-related factor-2-dependent genes. conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem.,, 278, 12029-12038.
9. Thimmulappa,R.K. et al. (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res., 62, 5196-5203.
10. Rangasamy,T. et al. (2004) Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest., 114, 1248-1259.
11. Cho,H.Y. et al. (2006) Nrf2 defends the lung from oxidative stress. Antioxid. Redox Signal., 8, 76-87.
12. Kwak,M.K. et al. (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem., 278, 8135-8145.
13. Enomoto,A. et al. (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci., 59, 169-177.
14. Chan,K, et al. (2001) An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen. Proc. Natl Acad. Sci. USA, 98, 4611-4616.
15. Rangasamy,T. et al. (2005) Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med., 202, 47-59.
16. Iizuka,T. et al. (2005) Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells, 10, 1113-1125.
17. Hu,X. et al. (2006) Accelerated ovarian failure induced by 4-vinyl cyclohexene diepoxide in Nrf2 null mice. Mol. Cell. Biol., 26 940-954.
18. Aoki,Y. et al. (2001) Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol. Appl. Pharmacol., 173, 154-160.
19. Ramos-Gomez,M. et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl Acad. Sci. USA 98, 3410-3415.
20. Iida,K. et al. (2004) Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res., 64, 6424-6431.
21. Braun,S. et al. (2002) Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell. Biol., 22 5492-5505.
22. Cho,H.Y. et al. (2004) The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J., 18, 1258-1260.
23. Suh,J.H. et al. (2004) Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl Acad. Sci. USA, 101, 3381-3386.
24. Ishii,Y. et al. (2005) Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J. Immunol., 175, 6968-6975.
25. Shih,A.Y. et al. (2005) Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J. Biol. Chem., 280, 22925-22936.
26. Yates,M.S. et al. (2007) Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect., 20, 109-117.
27. Kensler,T.W. et al. (2005) Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 14, 2605-2613.
28. Singh,A. et al. (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med., 3, e420.
29. Padmanabhan,B. et al. (2006) Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell. 21, 689-700.
30. Stacy,D.R. et al. (2006) Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck, 28, 813-818.
31. Wang,X.J. et al. (2007) Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity. Toxicol. Appl. Pharmacol., 225, 206-213.
32. Bromberg,K.D. et al. (2003) A two-drug model for etoposide action against human topoisomerase IIalpha. J. Biol. Chem., 278, 7406-7412.
33. Swift,L.P. et al. (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res., 66, 4863-4871.
34. Selvakumaran,M. et al. (2003) Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res., 63, 1311-1316.
35. Fujii,R. et al. (1994) Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn. J. Cancer Res., 85, 426-433.
36. Tew,K.D. (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res., 54, 4313-4320.
37. Chaney,S.G. et al. (1996) DNA repair: Enzymatic mechanisms and relevance to drug response. J. Natl Cancer Inst., 88, 1346-1360.
38. Xue,C. et al. (2007) p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res., 67, 10351-10360.
39. Tanabe,M. et al. (2003) Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res., 63, 8592-8595.
40. Wild,A.C. et al. (1999) Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J. Biol. Chem., 274, 33627-33636.
41. Chan,J.Y. et al. (2000) Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim. Biophys. Acta, 1517, 19-26.
42. Shih,A.Y. et al. (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci., 23, 3394-3406.
43. Kim,Y.C. et al. (2003) Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene, 22, 1860-1865.
44. Sasaki,H. et al. (2002) Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem., 277, 44765-44771.
45. Aleksunes,L.M. et al. (2007) Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol. Appl. Pharmacol., 226, 74-83.
46. Maher,J.M. et al. (2005) Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos., 33, 956-962.
47. Hayashi,A. et al. (2003) Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem. Biophys. Res. Commun., 310, 824-829.
48. He,C.H. et al. (2001) Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacttng protein. Implication for heme oxygenase-1 gene regulation. J. Biol. Chem., 276, 20858-20865.
49. Iida,K. et al. (2007) Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. Carcinogenesis, 28 2398-2403.
50. Cho,J.M. et al. (M) Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance. Cancer Lett., 260, 96-108.
51. Was,H. et al. (2006) Overexpression of heme oxygenase-1 in murine melanoma: Increased proliferation and viability of tumor cells, decreased survival of mice. Am. J. Pathol., 169, 2181-2198.
52. Jozkowicz,A. et al. (2007) Heme oxygenase-1 in tumors: Is it a false friend? Antioxid. Redox Signal., 9, 2099-2117.
53. Kim,A.R. et al. (2007) Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer, 60, 47-56.
54. Loboda,A. et al. (2007) Janus face of Nrf2-HO-1 axis in cancer-friend in chemoprevention, foe in anticancer therapy. Lung Cancer, 60, 1-3.
55. Nowis,D. et al. (2006) Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene, 25, 3365-3374.
56. Kim,H.J. et al. (2006) Heme oxygenase-1 attenuates the cisplatin-induced apoptosis of auditory cells via down-regulation of reactive oxygen species generation. Free Radic. Biol. Med., 40 1810-1819.
57. Wang,X.J. et al. (2006) Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res., 66, 10983-10994.